Thermosensitive Liposome Formulation with DPPG2 for Stable Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thermosensitive liposome formulations for cancer treatment, particularly for soft tissue sarcoma, face challenges in achieving stability for industry-scale manufacturing and long-term storage without compromising heat-induced drug delivery at temperatures above 39°C.
Innovation Solution
A thermosensitive liposome composition with a bilayer containing at least 15% 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG2) and a molar ratio of active pharmaceutical ingredients to lipids between 0.05 and 0.3, allowing for controlled release of drugs like doxorubicin, irinotecan, or gemcitabine at specific temperatures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thermosensitive liposome formulations are designed for heat-induced drug delivery at temperatures above 39°C, then drug release capability is improved, but stability during storage and manufacturing deteriorates
Solution Approach 1:
The patent modifies the lipid composition parameters, specifically incorporating DPPG2 at 15-40 mol% in the bilayer, which alters the phase transition temperature and membrane properties to achieve both storage stability and heat-responsive drug release. This parameter change allows the formulation to maintain structural integrity during storage while enabling controlled drug delivery at elevated temperatures.
Solution Approach 2:
The patent creates a composite liposome formulation combining multiple lipid components (DPPC, DSPC, DPPG2) with specific molar ratios. This composite structure integrates the stabilizing properties of certain lipids with the thermosensitive properties of others, resolving the contradiction between storage stability and heat-induced drug release capability.
2Reliability
If liposome formulations are optimized for therapeutic efficacy, then drug delivery performance is improved, but manufacturing complexity increases
Solution Approach 1:
The patent establishes specific parameter ranges for lipid composition (DPPG2 at 15-40 mol%, DPPC at 40-60 mol%, DSPC at 10-30 mol%) that ensure both therapeutic efficacy and manufacturability. These defined parameters provide a clear formulation specification that facilitates scalable manufacturing while maintaining drug delivery performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This formulation ensures stability and effective drug delivery to solid tumors, maintaining therapeutic efficacy and safety by controlling the release of active pharmaceutical ingredients at body temperature and above, facilitating scalable manufacturing and long-term storage.
Implementation Method 1
thermosensitive liposomes (TSL) have been proposed as drug-delivery systems... released a hydrophilic active pharmaceutical ingredient upon heating... thermosensitive liposome formulation that released a hydrophilic active pharmaceutical ingredient upon heating
Data Source
AI summary
The current invention provides thermosensitive liposomes and formulations thereof preferably for treating, ameliorating, delaying, curing and/or preventing cancer.